Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae196 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Donatella Schiavone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, Endocrine Surgery Unit, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Thyroidectomy, Graves Disease, Thyroid Gland, Iodides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Lugol solution is often administered to patients with Graves’ disease before surgery. The aim is to reduce thyroid vascularization and surgical morbidity, but its real effectiveness remains controversial. The present study was designed to evaluate the effects of preoperative Lugol solution on thyroid vascularization and surgical morbidity in patients with Graves’ disease undergoing total thyroidectomy.
Methods
Fifty-six patients undergoing total thyroidectomy for Graves’ disease were randomly assigned to receive 7 days of Lugol treatment (Lugol+ group, 29) or no Lugol treatment (LS– group, 27) before surgery in this single-centre and single-blinded trial. Preoperative hormone and colour Doppler ultrasonographic data for assessing thyroid vascularization were collected 8 days before surgery (T0) and on the day of surgery (T1). The primary outcome was intraoperative and postoperative blood loss. Secondary outcomes included duration of surgery, thyroid function, morbidity, vascularization, and microvessel density at final pathology.
Results
No differences in demographic, preoperative hormone or ultrasonographic data were found between LS+ and LS– groups at T0. At T1, free tri-iodothyronine (FT3) and free thyroxine (FT4) levels were significantly reduced compared with T0 values in the LS+ group, whereas no such variation was observed in the LS– group. No differences between T0 and T1 were found for ultrasonographic vascularization in either group, nor did the histological findings differ. There were no significant differences between the LS+ and LS– groups concerning intraoperative/postoperative blood loss (median 80 versus 94 ml respectively), duration of surgery (75 min in both groups) or postoperative morbidity.
Conclusion
Lugol solution significantly reduces FT3 and FT4 levels in patients undergoing surgery for Graves’ disease, but does not decrease intraoperative/postoperative blood loss, thyroid vascularization, duration of surgery or postoperative morbidity. Registration number NCT05784792 (https://www.clinicaltrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Oncology and Gastroenterology, Endocrine Surgery Unit, University of Padua, Padua, Italy.
- Department of Medicine, Institute of Radiology, University of Padua, Padua, Italy.
- Department of Medicine, Pathology Unit, University of Padua, Padua, Italy.
- Department of Pathology, Azienda ULSS2, Marca Trevigiana, Treviso, Italy.
- Department of Medicine, Endocrinology Unit, University of Padua, Padua, Italy.
ORCID-Profile: Caterina Mian, Maurizio Iacobone
Zitieren
APA
Schiavone, D., Crimì, F., Cabrelle, G., Pennelli, G., Sacchi, D., Mian, C., Torresan, F., & Iacobone, M. (2024). Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial. British Journal of Surgery. https://doi.org/10.1093/bjs/znae196
Vancouver
Schiavone D, Crimì F, Cabrelle G, Pennelli G, Sacchi D, Mian C, et al. Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial. British Journal of Surgery. 2024. doi:10.1093/bjs/znae196
BibTeX
@article{Schiavone2024,
author = {Schiavone, Donatella and Crimì, Filippo and Cabrelle, Giulio and Pennelli, Gianmaria and Sacchi, Diana and Mian, Caterina and Torresan, Francesca and Iacobone, Maurizio},
title = {Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae196}
}
EUVIMED